Cerebrospinal fluid ATP metabolites in multiple sclerosis

Abstract

Increased axonal energy demand and mitochondrial failure have been suggested as possible causes for axonal degeneration and disability in multiple sclerosis.

Our objective was to test whether ATP depletion precedes clinical, imaging and biomarker evidence for axonal degeneration in multiple sclerosis.

The method consisted of a longitudinal study which included 21 patients with multiple sclerosis. High performance liquid chromatography was used to quantify biomarkers of the ATP metabolism (oxypurines and purines) from the cerebrospinal fluid at baseline. The Expanded Disability Status Scale, MRI brain imaging measures for brain atrophy (ventricular and parenchymal fractions), and cerebrospinal fluid biomarkers for axonal damage (phosphorylated and hyperphosphorylated neurofilaments) were quantified at baseline and 3-year follow-up.

Central ATP depletion (sum of ATP metabolites >19.7 µmol/litre) was followed by more severe progression of disability if compared to normal ATP metabolites (median 1.5 versus 0, p< 0.05). Baseline ATP metabolite levels correlated with change of Expanded Disability Status Scale in the pooled cohort (r= 0.66, p= 0.001) and subgroups (relapsing—remitting patients: r= 0.79, p< 0.05 and secondary progressive/primary progressive patients: r= 0.69, p< 0.01). There was no relationship between central ATP metabolites and either biomarker or MRI evidence for axonal degeneration.

The data suggests that an increased energy demand in multiple sclerosis may cause a quantifiable degree of central ATP depletion. We speculate that the observed clinical disability may be related to depolarisation associated conduction block.

Keywords

Neurofilament phosphoforms multiple sclerosis prognosis disease subtype disability axonal injury

Get full access to this article

View all access options for this article.

References

Trapp BD , Peterson JP , Ransohoff RM , Rudick R. , Mörk S. , Bö L. Axonal transection in the lesions of multiple sclerosis. N Eng J Med 1998; 338: 278-285.

Trapp BD , Stys PK Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis . Lancet Neurol 2009; 8: 280-291.

Kapoor R. , Davies M. , Blaker P. , Hall S. , & Smith K. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration Ann Neurol, 2003; 53: 174-180.

Waxman SG Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 1982; 306: 1529-1533.

Waxman SG Nitric oxide and the axonal death cascade. Ann Neurol 2003; 53: 150-153.

Petzold A. CSF biomarkers for improved prognostic accuracy in acute CNS disease . Neurol Res 2007; 29: 691-708.

Barkhof F. , Calabresi PA , Miller DH , Reingold SC Imaging outcomes for neuroprotection and repair in multiple sclerosis trials . Nat Rev Neurol 2009; 5: 256-266.

Witte ME , Bö L. , Rodenburg RJ , et al. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 2009; 219: 193-204.

Mahad DJ , Ziabreva I. , Campbell G. , et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009; 132: 1161-1174.

10.

Su KG , Banker G. , Bourdette D. , Forte M. Axonal degeneration in multiple sclerosis: the mitochondrial hypothesis . Curr Neurol Neurosci Rep 2009; 9: 411-417.

11.

Blokhin A. , Vyshkina T. , Komoly S. , Kalman B. Variations in mitochondrial DNA copy numbers in MS brains. J Mol Neurosci 2008; 35: 283-287.

12.

Almeida A. , Heales SJ , Bolanos JP , Medina JM Glutamate neurotoxicity is associated with nitric oxide-mediated mitochondrial dysfunction and glutathione depletion. Brain Res 1998; 790: 209-216.

13.

Jacobson J. , Duchen MR , Hothersall J. , Clark JB , Heales SJ Induction of mitochondrial oxidative stress in astrocytes by nitric oxide precedes disruption of energy metabolism. J Neurochem 2005; 95: 388-395.

14.

Vanlangenakker N. , Van den Berghe T. , Krysko DV , Festjens N. , Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 2008; 8: 207-220.

15.

Baud O. , Li J. , Zhang Y. , Neve RL , Volpe JJ , Rosenberg PA Nitric oxide-induced cell death in developing oligodendrocytes is associated with mitochondrial dysfunction and apoptosis-inducing factor translocation . Eur J Neurosci 2004; 20: 1713-1726.

16.

Lang-Rollin ICJ , Rideout HJ , Noticewala M. , Stefanis L. Mechanisms of caspase-independent neuronal death: energy depletion and free radical generation . J Neurosci 2003; 23: 11015-11025.

17.

Humphrey SM , Holliss DG , Seelye RN Myocardial adenine pool depletion and recovery of mechanical function following ischemia. Am J Physiol 1985; 248: H644-H651.

18.

Domanski L. , Safranow K. , Ostrowski M. , et al. Oxypurine and purine nucleoside concentrations in renal vein of allograft are potential markers of energy status of renal tissue. Arch Med Res 2007; 38: 240-246.

19.

De Jong JW , Keijzer E. , Huizer T. , Schoutsen B. Ischemic nucleotide breakdown increases during cardiac development due to drop in adenosine anabolism/catabolism ratio. J Mol Cell Cardiol 1990; 22: 1065-1070.

20.

Humphrey SM , Holliss DG , Cartner LA The influence of inhibitors of the atp degradative pathway on recovery of function and high energy phosphate after transient ischemia in the rat heart. J Mol Cell Cardiol 1986; 18(Suppl 4): 55S-59S.

21.

Amorini AM , Petzold A. , Tavazzi B. , et al. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 2009; 42: 1001-1006.

22.

Petzold A. , Eikelenboom MJ , Keir G. , et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: A 3-year follow-up study. J Neurol Neurosurg Psychiatry 2005; 76: 206-211.

23.

McDonald WI , Compston A. , Edan G. , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.

24.

Kurtzke JF Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.

25.

Kalkers NF , Bergers E. , Castelijns JA , et al. Optimizing the association between disability and biological markers in MS. Neurology 2001; 57: 1253-1258.

26.

Petzold A. , Keir G. , Green AJE , Giovannoni G. , Thompson EJ A specific ELISA for measuring neurofilament heavy chain phosphoforms . J Immunol Methods 2003; 278: 179-190.

27.

Narayana PA , Doyle TJ , Lai D. , Wolinsky JS Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43: 56-71.

28.

Clark JB N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction . Dev Neurosci 1998; 20: 271-276.

29.

De Stefano N. , Filippi M. MR spectroscopy in multiple sclerosis . J Neuroimaging 2007; 17(Suppl 1): 31S-35S.

30.

Regenold WT , Phatak P. , Makley MJ , Stone RD , Kling MA Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression . J Neurol Sci 2008; 275: 106-112.

31.

Smith KJ Conduction properties of central demyelinated and remyelinated axons, and their relation to symptom production in demyelinating disorders. Eye (Lond) 1994; 8: 224-237.

32.

Davey GP , Canevari L. , Clark JB Threshold effects in synaptosomal and nonsynaptic mitochondria from hippocampal CA1 and paramedian neocortex brain regions. J Neurochem 1997; 69: 2564-2570.

33.

Davey GP , Peuchen S. , Clark JB Energy thresholds in brain mitochondria. potential involvement in neurodegeneration . J Biol Chem 1998; 273: 12753-12757.

34.

Rush AM , Dib-Hajj SD , Liu S. , Cummins TR , Black JA , Waxman SG A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Acad Sci U S A 2006; 103: 8245-8250.

35.

Craner MJ , Kataoka Y. , Lo AC , Black JA , Baker D. , Waxman SG Temporal course of upregulation of Na(v)1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis . J Neuropathol Exp Neurol 2003; 62: 968-975.

36.

Black JA , Newcombe J. , Trapp BD , Waxman SG Sodium channel expression within chronic multiple sclerosis plaques . J Neuropathol Exp Neurol 2007; 66: 828-837.

37.

Waxman SG Acquired channelopathies in nerve injury and MS. Neurology 2001; 56: 1621-1627.

38.

Altmann DR , Jasperse B. , Barkhof F. , et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 2009; 72: 595-601.